Study of a nanovaccine targeting cholesteryl ester transfer protein against atherosclerosis
10.3969/j.issn.1674-8115.2017.11.003
- VernacularTitle:胆固醇酯转移蛋白纳米疫苗抗动脉粥样硬化的初步实验研究
- Author:
sha Sha YOU
1
;
yong Yong LI
;
qin Hai DONG
;
Bin HE
Author Information
1. 上海交通大学 医学院附属新华医院麻醉与重症医学科
- Keywords:
nano;
vaccine;
cholesteryl ester transfer protein;
atherosclerosis
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2017;37(11):1463-1468
- CountryChina
- Language:Chinese
-
Abstract:
Objective· To prepare nanocarriers capable of improving the immunogenicity of cholesteryl ester transfer protein (CETP) hapten. Methods · Prepare CETP polypeptide modified by thiol in Fmoc, then Sulfo-SMCC were used to prepare CETP peptide-ovalbumin (OVA) nanoparticle and CETP peptide - OVA molecule conjugates in a two-step reaction scheme. The particle size and zeta potential of nanovaccine were determined and the morphology was observed. New Zealand White rabbits were vaccinated by subcutaneous injection of vaccine and serum collected from rabbits was detected by ELISA assay for the analysis of antibodies, high density lipoprotein cholesterol(HDL-C) and low density lipoprotein cholesterol (LDL-C). The rabbits were randomly allocated to the PBS group (n=3), traditional vaccine group (n=3), and nanovaccine group (n=3). Results · Nanovaccine targeting CETP were successfully synthesized, with about 70 nm in size and about -8.81 mV in zeta potential, and possessed homogeneous spherical shape under transmission electron microscopy. Compared with traditional vaccine group, rabbits in nanovaccine group got higher antibodies. Conclusion · Nanovaccine improve immunogenicity of CETP haptens, and stimulate experiment rabbits to produce higher antibodies.
